Skip to main content
. 2019 Oct 7;116(43):21715–21726. doi: 10.1073/pnas.1912858116

Fig. 5.

Fig. 5.

Validation of PRC2 and DREAM complex disruption in type B and C tumors, respectively. (A) GSEA analysis of the PRC2 (Left) and DREAM (Right) target genes from each type. (B, Left) Coimmunoprecipitation studies using 5 tumors per type for EZH1 then probed for anti-EED and anti-SUZ12. (B, Right) Coimmunoprecipitation studies using 5 tumors per type for LIN37 then probed for anti-FoxM1, anti-MYBL2, and anti-RBL2. (C) GSEA analysis shows that HOX genes are enriched in type B (Left) and cell-cycle genes in type C (Right). (D) qRT-PCR analysis measuring expression levels of type-specific up-regulated genes and in 293T and arachnoid cells. (Left) Cells were transfected with either wild-type hEZH1 or hEZH1 ΔSET (dominant-negative EZH1). (Right) Cells were transfected with either wild-type hLIN37 or dominant-negative hLIN37 (left side) or either wild-type hLIN52 or dominant-negative hLIN52 (right side).